TDF switch.

[Royal36]

TDF switch effective in Asian chronic HBV patients
Posted in Hepatitis News
Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients. Administration of TDF resulted in a sustained virological response in the majority of nucleos ide analogue -experienced patients after nearly 2 years of follow-up, report the researchers.

[sorte]

84% svr because they used other old antivirals like lamivudine before and developed resistance ?

[Royal36]

84% it is a good outcome i guess.

[Royal36]

But the findings also showed that those with a high baseline level of hepatitis B virus (HBV) were significantly less likely to achieve a sustained virological response than patients with lower baseline levels.

The Hong Kong-based study involved 252 NUC-experienced patients who switched from treatment with other antiviral agents, such as lamivudine and adefovir dipivoxil, to TDF (300 mg/day) between 2009 and 2013, primarily due to drug resistance. Of these, 152 had persistent viraemia at the time of the switch while the remaining 100 had undetectable HBV DNA.

At a median of 22 months, 214 (84.9%) TDF-treated patients had achieved a sustained virological response, defined as HBV DNA levels of less than 20 IU/mL until the final follow-up visit. And, in the remaining patients, HBV DNA levels were low at the final follow-up, at a median of 1.48 log IU/mL, the team reports.